快速生长预测着高产量的药物筛选市场
NEW YORK (Reuters Health) - A new report from the market research firm Frost & Sullivan predicts the US market for high-throughput screening of drug compounds will reach $3.6 billion in 2004, reflecting a 15% compound annual growth rate from its current size of $2.3 billion.
Growth should arise not only from the needs of drug discovery firms, but also from high demand by contract research organizations (CROs) and the consumables-supplies and instrumentation segments of the market.
, http://www.100md.com
The major challenges to growth, according to Frost & Sullivan, are the long lead time in assay development, inefficient selection of compounds for pre-clinical development and the overall high cost of the process. The long lead time in assay development arrests new investment in high-throughput screening technologies, said Luz Del Pietro, a Frost & Sullivan analyst.
The report predicts that by 2004, researchers will be testing an average of 7 million compounds per week. To reach that target, advances in micro-electromechanical systems and microsystems technology devices will increase in efficiency over the next 3 years.
, 百拇医药
Frost & Sullivan said that the consumables segment of the market generated revenues of $855 million in 2000. The segment includes supplies such as microplates, probes, scintillation cocktails, media culture, DNA products, signaling and reagent kits. All of the products in the segment are necessary to perform the variety of tasks required by high-throughput screening, according to the report.
The study's authors project the consumables segment will grow at an annual rate of 25% to $1.3 billion by 2004. The growth rate for the instrumentation sector also is positive, but is not expected to be as high as the consumables and supplies.
, 百拇医药
Growth in the CRO segment of the market should be approximately 20% per year over the next 3 years, according to Frost & Sullivan. CROs have entered high-throughput screening in the past few years as more chemistry divisions of biotechnology and pharmaceutical companies have been phased out, Frost & Sullivan noted. As a consequence, CROs can offer fast turnaround times for drug researchers and prevent the drug discovery process from becoming unnecessarily prolonged.
, 百拇医药
Total revenue from the CRO segment could reach $756 million in 2004, they predict.
Not surprisingly, pharmaceutical and biotechnology companies are projected to remain the major consumers of high-throughput screening technologies because of the steady increase in the cost of developing new drugs.
Even though more companies are outsourcing their research, Frost & Sullivan noted that high-throughput screening expenditures at pharma and biotech companies reached 22% of research budgets in 2000 and predicted the number would increase consistently over the next 4 years. The percentage will increase even as the outsourcing trend continues, according to the report., http://www.100md.com
Growth should arise not only from the needs of drug discovery firms, but also from high demand by contract research organizations (CROs) and the consumables-supplies and instrumentation segments of the market.
, http://www.100md.com
The major challenges to growth, according to Frost & Sullivan, are the long lead time in assay development, inefficient selection of compounds for pre-clinical development and the overall high cost of the process. The long lead time in assay development arrests new investment in high-throughput screening technologies, said Luz Del Pietro, a Frost & Sullivan analyst.
The report predicts that by 2004, researchers will be testing an average of 7 million compounds per week. To reach that target, advances in micro-electromechanical systems and microsystems technology devices will increase in efficiency over the next 3 years.
, 百拇医药
Frost & Sullivan said that the consumables segment of the market generated revenues of $855 million in 2000. The segment includes supplies such as microplates, probes, scintillation cocktails, media culture, DNA products, signaling and reagent kits. All of the products in the segment are necessary to perform the variety of tasks required by high-throughput screening, according to the report.
The study's authors project the consumables segment will grow at an annual rate of 25% to $1.3 billion by 2004. The growth rate for the instrumentation sector also is positive, but is not expected to be as high as the consumables and supplies.
, 百拇医药
Growth in the CRO segment of the market should be approximately 20% per year over the next 3 years, according to Frost & Sullivan. CROs have entered high-throughput screening in the past few years as more chemistry divisions of biotechnology and pharmaceutical companies have been phased out, Frost & Sullivan noted. As a consequence, CROs can offer fast turnaround times for drug researchers and prevent the drug discovery process from becoming unnecessarily prolonged.
, 百拇医药
Total revenue from the CRO segment could reach $756 million in 2004, they predict.
Not surprisingly, pharmaceutical and biotechnology companies are projected to remain the major consumers of high-throughput screening technologies because of the steady increase in the cost of developing new drugs.
Even though more companies are outsourcing their research, Frost & Sullivan noted that high-throughput screening expenditures at pharma and biotech companies reached 22% of research budgets in 2000 and predicted the number would increase consistently over the next 4 years. The percentage will increase even as the outsourcing trend continues, according to the report., http://www.100md.com